WO2008023362A3 - Traitement du cancer - Google Patents

Traitement du cancer Download PDF

Info

Publication number
WO2008023362A3
WO2008023362A3 PCT/IL2007/001009 IL2007001009W WO2008023362A3 WO 2008023362 A3 WO2008023362 A3 WO 2008023362A3 IL 2007001009 W IL2007001009 W IL 2007001009W WO 2008023362 A3 WO2008023362 A3 WO 2008023362A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methotrexate
treatment
combination
a3ar agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/001009
Other languages
English (en)
Other versions
WO2008023362A2 (fr
Inventor
Pnina Fishman
Sara Bar-Yehuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of WO2008023362A2 publication Critical patent/WO2008023362A2/fr
Publication of WO2008023362A3 publication Critical patent/WO2008023362A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le traitement thérapeutique d'un cancer par une administration combinée de méthotrexate et d'un agoniste du récepteur A3 de l'adénosine. L'invention concerne également des méthodes de traitement thérapeutique comprenant cette administration combinée, les compositions pharmaceutiques utiles dans ces procédés et aussi l'utilisation de n'importe lequel de ces agents actifs pour préparer cette composition pharmaceutique.
PCT/IL2007/001009 2006-08-21 2007-08-16 Traitement du cancer Ceased WO2008023362A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83886306P 2006-08-21 2006-08-21
US83886206P 2006-08-21 2006-08-21
US60/838,862 2006-08-21
US60/838,863 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008023362A2 WO2008023362A2 (fr) 2008-02-28
WO2008023362A3 true WO2008023362A3 (fr) 2008-07-03

Family

ID=38578621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001009 Ceased WO2008023362A2 (fr) 2006-08-21 2007-08-16 Traitement du cancer

Country Status (1)

Country Link
WO (1) WO2008023362A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2331542B1 (fr) * 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services Antagonistes et agonistes partiels des récepteurs de l'adénosine a3
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2331543A4 (fr) * 2008-09-26 2013-06-19 Agency Science Tech & Res Dérivés 3-désazanéplanocine
WO2011010306A1 (fr) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. Ligands du récepteur a3 de l’adénosine modulant la pigmentation
KR101192097B1 (ko) 2009-12-17 2012-10-18 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 대장암 치료용 약제학적 조성물
KR101192063B1 (ko) 2010-02-02 2012-10-17 이화여자대학교 산학협력단 염증성 질환의 예방 및 치료용 약제학적 조성물
WO2011074903A2 (fr) * 2009-12-17 2011-06-23 이화여자대학교 산학협력단 Composition pharmaceutique incluant un agoniste de récepteur d'adénosine a3
KR101181627B1 (ko) * 2009-12-17 2012-09-10 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 전립선암 치료용 약제학적 조성물
KR101207755B1 (ko) * 2010-02-02 2012-12-03 이화여자대학교 산학협력단 염증성 질환의 예방 및 치료용 약제학적 조성물
IL300132A (en) * 2023-01-23 2024-08-01 Can Fite Biopharma Ltd Pancreatic cancer treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019360A2 (fr) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Compositions pharmaceutiques contenant un antagoniste ou un agoniste de recepteur d'adenosine
WO2004038006A2 (fr) * 2002-10-25 2004-05-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleosides puriques
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
WO2006031505A1 (fr) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de purine comme agonistes du recepteur d'adenosine a3 et a1
WO2006034190A2 (fr) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Dérivés de la purine et leurs procédés d'utilisation
WO2006059328A1 (fr) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Traitement anti-inflammatoire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019360A2 (fr) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Compositions pharmaceutiques contenant un antagoniste ou un agoniste de recepteur d'adenosine
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
WO2004038006A2 (fr) * 2002-10-25 2004-05-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleosides puriques
WO2006031505A1 (fr) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de purine comme agonistes du recepteur d'adenosine a3 et a1
WO2006034190A2 (fr) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Dérivés de la purine et leurs procédés d'utilisation
WO2006059328A1 (fr) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Traitement anti-inflammatoire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHMAN P ET AL: "The anti-cancer effect of A3 adenosine receptor agonists: A novel, targeted therapy", IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS IN MEDICINAL CHEMISTRY 200708 NL, vol. 7, no. 4, August 2007 (2007-08-01), pages 298 - 303, XP008089962, ISSN: 1871-5222 *
JOSHI BHALCHANDRA V ET AL: "Purine derivatives as ligands for A(3) adenosine receptors", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 5, no. 13, 2005, pages 1275 - 1295, XP008089968, ISSN: 1568-0266 *
PARFITT, K.: "Martindale, The complete drug reference, Thrity-second edition", 1999, PHARMACEUTICAL PRESS, LONDON, UK, XP002478059 *

Also Published As

Publication number Publication date
WO2008023362A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008023362A3 (fr) Traitement du cancer
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007092620A3 (fr) Formulations stables et leurs procedes de preparation et d'utilisation
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2012027065A3 (fr) Polythérapie pour traiter des maladies
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
WO2008105773A3 (fr) Système pour l'administration ciblée d'agents thérapeutiques
IL196775A (en) Annotations 4,2-Bis (3-Methyl-Morpholine-4-Yl) -7-Phenyl-Pyrido [3,2- d] Pyrimidine, Containing and Using Pharmaceuticals as Drugs and Drug Manufacturing
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
IL207928A (en) Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity
IL192454A (en) Solid Pharmaceuticals Containing S-Adenosylmethionine
WO2009088673A3 (fr) Composition pharmaceutique
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
PL2185561T3 (pl) Pochodne 1,2,3,4-tetrahydropirolo(1,2-a)pirazyno-6-karboksamidów i 2,3,4,5-tetrahydropirolo(1,2-a)-diazepino-7-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne
WO2007035783A3 (fr) Preparations combinees d'analogues de cytidine et d'agents platine
WO2009086077A3 (fr) Antagonistes des récepteurs de l'adénosine a1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07805482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07805482

Country of ref document: EP

Kind code of ref document: A2